Astria Therapeutics (ATXS) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 11, 2025, at company headquarters in Boston, MA.

• Proxy materials, including the 2024 Annual Report, are available online and by request.

• Shareholders are invited to attend and vote on key proposals.

Voting matters and shareholder proposals

• Election of three Class I Directors for a three-year term until the 2028 annual meeting.

• Approval of an amendment to the 2015 Stock Incentive Plan to add 5,500,000 shares.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2025.

• Advisory vote on executive compensation.

• Board recommends voting "FOR" all proposals.

Board of directors and corporate governance

• Nominees for Class I Director: Fred Callori, Michael Kishbauch, and Jill C. Milne.

• Directors to serve until 2028 if elected.